Acronym SEABIOTECH
Category
Marine Biotechnology
Title From sea-bed to test-bed: harvesting the potential of marine microbes for industrial biotechnology Programme FP7
Instrument (FP6)
Contact Type (FP7)
Strand (Interreg)
FP7 - Collaborative Project targeted to a Special Group (such as SMEs)
Theme (FP7)
Activity Area (FP6)
Regional Area (Interreg)
Action (COST)
KBBE – Food, Agriculture and Fisheries, and Biotechnology
Specific Programme (FP7)
Cooperation
Funding source European Coordinator Brian McNeil Coordinator email b.mcneil@strath.ac.uk
Coordinator institution
NA
Institutions involved
NA - Axxam SpA (Italy) ,
NA - Horizon Discovery Ltd (United Kingdom) ,
NA - Ingenza Ltd (United Kingdom) ,
ULUND - Lund University (Sweden) ,
NA - Marine Biopolymers Ltd (United Kingdom) ,
MATIS - Matis Ltd (Iceland) ,
NA - National Research Council - Institute of Marine Engineering (Italy) ,
NA - Novamen SAS (France) ,
NA - PHARMAQ AS (Norway) ,
NA - Prokazyme Ehf (Iceland) ,
SAMS - Scottish Association for Marine Science (United Kingdom) ,
VTT - Technical Research Centre of Finland (Finland) ,
JMU - University of Würzburg (Germany) ,
Start year 2012 End year 2016 Funding (€) € 9,928,143 Website http://spider.science.strath.ac.uk/seabiotech/ Summary SeaBioTech is a 48-month project designed and driven by SMEs to create innovative marine bio-discovery pipelines as a means to convert the potential of marine biotechnology into novel industrial products for the pharmaceutical (human and aquaculture), cosmetic, functional food and industrial chemistry sectors. SeaBioTech will reduce barriers to successful industrial exploitation of marine biodiversity for companies more accustomed to terrestrial biotechnology. SeaBioTech directly addresses five key challenges to remove bottlenecks in the marine bio-discovery pipeline, leading to; (1) Improvements in the quality of marine resources available for biotechnological exploitation; (2) Improvement in technical aspects of the bio-discovery pipeline to shorten time to market; (3) Developing sustainable modes of supply of raw materials for industry. The two last challenges centre on enabling activities to enhance the marine bio-discovery process: first, clarification of legal aspects to facilitate access to marine resources, their sustainable use, and their secure exploitation; second, to create an improved framework for access to marine biotechnology data and research materials. To achieve its goals, SeaBioTech brings together complementary and world-leading experts, integrating biology, genomics, natural product chemistry, bioactivity testing, industrial bioprocessing, legal aspects, market analysis and knowledge exchange. The expertise assembled within the consortium reflects the industry-defined needs, from the SME partner's initial definition of market and product opportunities to their ultimate proof-of-concept demonstration activities. SeaBioTech will have a significant impact on research and technology, on innovation, on European competitiveness and on economic growth. It will provide a model to accelerate the development of European biotechnology into a world leading position.
(1) Provide a pipeline of commercially viable products based on relevant bio-activity screening of samples of marine origin; (2) Develop efficient standardized processes and methods across the bio-discovery pipeline Introduce industrial bio-processing methods suitable for commercial production of marine-sourced materials; (3) Clarify, harmonize and potentially simplify the legal aspects related to marine bio-discovery processes; (4) Create a central EU platform and bio-bank based on an integrated approach to bio-discovery pipelines for future use by other consortia, academia and companies.
Keywords
Bioactive compounds;
Nutraceutical substances;
Human food;
Biomaterial;
Metagenomic;
Genetic;
Engineering;
Human health;
Policy;
Pharmaceuticals;
Animal welfare;
Bioproduct;
Microbial communities;
Bioprospecting;
Genomic;
Cosmetics;
Marine Region
60
Western Ionian Sea (GSA 19)
36
Iceland Grounds (27.Va)
2
Marine Region Map
